Text and Data Mining valid from 2018-01-01
Received: 10 July 2017
Accepted: 20 November 2017
First Online: 4 January 2018
: K.S.F., J.L. and S.R.-R. are employees of Novo Nordisk, a pharmaceutical company focused on class B GPCRs for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. The remaining authors declare no competing financial interests.